PTPA and cancer: Considering that PP2A activity is a key determinant of NELF-A phosphorylation in cancer, the pharmacological reactivation of PP2A would be highly effective in suppressing the expression of IEGs and growth-promoting genes, and thus it may provide significant benefits in cancer treatment.